Drug news
Pixuvri (CellTherapeutics) is refiled at the FDA for NHL
The FDA has accepted the resubmission of Pixuvri(pixantrone dimaleate) from Cell Therapeutics as a single-agent treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy.The FDA has not required an additional trial. The FDA has set 24 April 2012 as the new Prescription Drug User Fee Act action date. The drug is also filed in the EU.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins